Sept. 14, 2026
Europe Correspondent
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.
It’ll be the company formerly known as Novo Nordisk.
The Danish firm, whose diabetes and obesity drugs have become household names, said Monday it would embrace “Novo” as its new brand, part of a culture shifts that aims to signal the company will “move ahead with greater focus, speed, and impact.”
Advertisement
The rebrand, featuring the slogan “Lasting Health Starts Now,” is part of Novo’s turnaround attempt. The company, which was first out of the gate in the modern GLP-1 era, has since fallen behind Eli Lilly in the obesity market and underwhelmed investors with its pipeline. Shares are down nearly 20% over the past year, part of a broader collapse in the company’s stock since its peak in 2024, when it was Europe’s most valuable company.
STAT+ Exclusive Story
Already have an account?Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account?Log in
Monthly
$39
Totals $468 per year
$39/monthGet StartedTotals $468 per year
Starter
$30
for 3 months, then $399/year
$30 for 3 monthsGet StartedThen $399/year
Annual
$399
Save 15%
$399/yearGet StartedSave 15%
11+ Users
Custom
Savings start at 25%!
Request A QuoteRequest A QuoteSavings start at 25%!
2-10 Users
$300
Annually per user
$300/yearGet Started$300 Annually per user
View All PlansTo read the rest of this story subscribe to STAT+.
SubscribeLog InObesity,
Pharmaceuticals,
STAT+Submit a correction requestReprintsEurope Correspondent
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.
Newsletter
Understand how science, health policy, and medicine shape the world every day
